Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an announcement.
MAIA Biotechnology presented a scientific poster titled “Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and ICI in the THIO-101 Trial” at the European Lung Cancer Congress 2026 in Copenhagen, Denmark, on March 27, 2026. The poster, simultaneously posted on the company’s website, highlights clinical findings from the THIO-101 trial in relapsed non-small cell lung cancer and underscores MAIA’s efforts to position its investigational therapy Ateganosine in combination with immune checkpoint inhibitors as a potential long-term treatment option in this challenging oncology segment.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a biopharmaceutical company focused on developing oncology therapies, including novel agents for difficult-to-treat cancers such as non-small cell lung cancer. The company targets patients with relapsed disease and seeks to improve long-term outcomes by combining its investigational drugs with established immunotherapies.
Average Trading Volume: 1,053,401
Technical Sentiment Signal: Strong Sell
Current Market Cap: $83.73M
Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.